Friday 6 November 2026
Export NEO’s income statement to Excel — free account
NeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
16.63
0.14
+0.85%
Follow NEO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 5 | 5 |
| (12.42%) | (11.56%) | (6.33%) | (3.94%) | ||
| (7.21%) | (6.73%) | (3.78%) | (2.35%) | ||
ROIC |
(7.11%) | (6.48%) | (4.20%) | (2.97%) | |
Return on Tangible Assets |
(28.98%) | (26.61%) | (14.55%) | (8.50%) | |
Average Days of Receivables |
79.91 | 81.92 | 83.55 | 98.88 | |
Free Cash Flow per Share |
(0.15) | (0.02) | (0.04) | (0.21) | |
Free Cash Flow |
(19.71) | (3.02) | (5.29) | (26.52) | |
Capital Expenditures |
(24.94) | (25.44) | (27.34) | (30.80) | |
| Other line items | |||||
Cash ROIC |
(1.47%) | (0.23%) | (0.40%) | (2.01%) | |
Accounts Receivable Turnover |
4.70 | 4.68 | 4.67 | 4.27 | |
Accounts Payable Turnover |
18.48 | 20.14 | 17.74 | 15.67 | |
Inventory Turnover |
14.93 | 14.23 | 14.02 | 16.13 | |
Average Days of Payables |
20.40 | 22.29 | 17.80 | 27.62 | |
Days of Inventory on Hand |
25.24 | 25.68 | 23.05 | 21.39 | |
Tax Rate |
(0.02) | (0.03) | (0.05) | (0.11) | |
Research and Development Expense of Revenue |
5.10% | 4.88% | 4.98% | 4.99% | |
Selling, General and Administrative Expense of Revenue |
50.23% | 48.80% | 46.86% | 45.96% | |
Share Based Compensation of Revenue |
5.68% | 5.39% | 4.72% | 4.41% | |
Interest Coverage |
(30.88) | (38.89) | (26.52) | (15.21) | |
Operating CF/Net income |
(0.05) | (0.23) | (0.42) | (0.13) | |
Depreciation/Fixed assets |
0.82 | 0.82 | 0.83 | 0.78 | |
Capex/Depreciation |
(0.36) | (0.37) | (0.41) | (0.46) | |
Revenue per Share |
5.68 | 5.78 | 5.91 | 6.13 | |
Operating CF per Share |
0.04 | 0.17 | 0.17 | 0.03 | |
Capex per Share |
(0.19) | (0.20) | (0.21) | (0.24) | |
Capex to Sales |
0.03 | 0.03 | 0.04 | 0.04 |
Columns are period end dates · fundamentals updated 2 Nov 2026